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To identify distinct biological pathways of glucose metabolism, we
conducted a systematic evaluation of biochemical changes after an
oral glucose tolerance test (OGTT) in a community-based popula-
tion. Metabolic proﬁling was performed on 377 nondiabetic Framing-
ham Offspring cohort participants (mean age 57 years, 42% women,
BMI 30 kg/m
2) before and after OGTT. Changes in metabolite levels
were evaluated with paired Student t tests, cluster-based analyses,
and multivariable linear regression to examine differences associ-
ated with insulin resistance. Of 110 metabolites tested, 91 signiﬁ-
cantly changed with OGTT (P # 0.0005 for all). Amino acids,
b-hydroxybutyrate, and tricarboxylic acid cycle intermediates de-
creased after OGTT, and glycolysis products increased, consistent
with physiological insulin actions. Other pathways affected by OGTT
included decreases in serotonin derivatives, urea cycle metabolites,
and B vitamins. We also observed an increase in conjugated, and a
decrease in unconjugated, bile acids. Changes in b-hydroxybutyrate,
isoleucine, lactate, and pyridoxate were blunted in those with insulin
resistance. Our ﬁndings demonstrate changes in 91 metabolites rep-
resenting distinct biological pathways that are perturbed in response
to an OGTT. We also identify metabolite responses that distinguish
individuals with and without insulin resistance. These ﬁndings sug-
gest that unique metabolic phenotypes can be unmasked by OGTT in
the prediabetic state. Diabetes 62:2689–2698, 2013
D
iabetes affects .1 in 10 adults 20 years of age or
older in the U.S., and more than one-third of all
adults have prediabetes (1). Changes in tradi-
tional measures of glucose and insulin metab-
olism are known to occur years before the diagnosis of
diabetes is made (2). Using high-throughput proﬁling of
metabolic status, we have shown that elevations in plasma
branched-chain and aromatic amino acids are also able to
predict future diabetes in otherwise normoglycemic, healthy
adults (3). Similarly, lipid proﬁling has demonstrated
novel perturbations in triacylglycerol distribution that
signal future diabetes risk (4). These ﬁndings highlight
how emerging technologies are able to broaden our per-
spective on early disease states, potentially lending in-
sights into biological mechanisms that underlie diabetes
and metabolic disease. Characterizing early metabolic changes
may also lead to the early identiﬁcation of at-risk indivi-
duals and may prompt the initiation of proven preventive
strategies (5).
The oral glucose tolerance test (OGTT) provides a dy-
namic view of glucose and insulin physiology and has been
widely used for decades to diagnose diabetes (6,7). There-
fore, we conducted a systematic evaluation of biochemical
changes after OGTT in a community-based population,
with the goal of providing a broad view of the metabolic
response to a glucose challenge. An important advantage of
proﬁling plasma samples before and after glucose ingestion
is that each individual is able to serve as their own bi-
ological control. In addition to attenuating noise attributable
to interindividual variation, this approach limits confound-
ing effects of diet, medications, and other inputs that impact
the human metabolome. We used a liquid chromatography/
mass spectrometry (LC/MS)–based platform that allowed
highly speciﬁci d e n t i ﬁcation of small molecules in a tar-
geted manner. In prior pilot studies, our group has shown
that metabolite excursions with OGTT revealed a switch
from catabolism to anabolism, largely attributable to insulin
actions (8). In the current study, we sought to evaluate
perturbations with OGTT in an expanded panel of metab-
olites and in a more comprehensive population-based
sample with a high propensity for the development of di-
abetes, and to investigate these changes in individuals with
and without insulin resistance.
RESEARCH DESIGN AND METHODS
Study sample. The Framingham Heart Study (FHS) Offspring cohort is
a prospective, observational, community-based cohort (9). The children (and
their spouses) of FHS participants were recruited in 1971 and have been fol-
lowed with serial examinations approximately every 4 years. Sample selection
procedures have previously been described (3). In brief, study participants
included in this analysis attended the ﬁfth examination (1995–1998), and they
underwent metabolic proﬁling on pre– and post–glucose challenge samples.
A total of 377 individuals free of diabetes were included in this analysis.
Participants provided informed consent, and the study protocol was approved
by the institutional review board at Boston University Medical Center.
Clinical assessment. Subjects underwent a 2-h, 75-g OGTT after a 12-h
overnight fast. Blood samples were obtained before and after OGTT. Diabetes
was deﬁned as a fasting glucose $126 mg/dL, nonfasting blood glucose $200
mg/dL, or the use of insulin or other hypoglycemic medications. Hypertension
was deﬁned as a systolic blood pressure (SBP) $140 mmHg, a diastolic blood
pressure $90 mmHg, or current use of medication to treat hypertension.
Participants smoking cigarettes regularly during the prior year were considered
current smokers. The homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated as fasting insulin (mIU/mL) 3 fasting glucose
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ORIGINAL ARTICLE(mmol/mL)/22.5 (10) and insulin resistance deﬁned as the top quartile of
HOMA-IR from the entire FHS Offspring cohort free of diabetes at the ﬁfth
examination cycle. Although individuals were not selected based on insulin
resistance status, the sample was selected based on a high propensity for the
future development of diabetes as previously described (3).
Metabolic syndrome was deﬁned as the presence of any three of the fol-
lowing ﬁve criteria (11): waist circumference $40 inches in men or $35 inches
in women, triglycerides $150 mg/dL or treatment with a ﬁbrate or niacin, HDL
cholesterol ,40 mg/dL in men or ,50 mg/dL in women or treatment with
a ﬁbrate or niacin, SBP $130 mmHg or diastolic blood pressure $85 mmHg or
drug treatment for hypertension, or fasting glucose $100 mg/dL or drug
treatment for elevated glucose.
Metabolic proﬁling. Blood samples were collected after an overnight fast,
both immediately prior to and 2 h after administration of a standard 75-g OGTT.
Samples were immediately centrifuged and stored at 280°C until assayed. The
details of the LC/MS platform used to proﬁle analytes have been previously
described (3). In brief, data were acquired using a 4000 QTRAP triple quad-
rupole mass spectrometer (Applied Biosystems/Sciex, Foster City, CA) and
a multiplexed LC system consisting of two 1200 Series pumps (Agilent Tech-
nologies) and an HTS PAL autosampler (Leap Technologies). Polar plasma
metabolites were measured using hydrophilic interaction chromatography and
tandem MS with electrospray ionization and multiple reaction monitoring
scans in the positive ion mode as previously detailed (3). We also performed
a complementary analysis of small molecules preferentially ionized using
negative mode electrospray ionization under basic conditions and used hy-
drophilic interaction chromatography to assess organic acids and other in-
termediary metabolites. Formic acid, ammonium acetate, and LC/MS-grade
solvents (Sigma-Aldrich) were used, and samples were prepared by adding
120 mL of extraction solution (80% methanol plus the internal standards
inosine-
15N4, thymine-d4, and glycocholate-d4)t o3 0mL of plasma. The sam-
ples were centrifuged (10 min, 10,000 rpm, 4°C) and supernatants were in-
jected directly. For quality control, internal standard peak areas were monitored
and individual samples with peak areas differing by .2 SD from the group
mean were reanalyzed. For this analysis, 54% of the metabolites had a co-
efﬁcient of variation #10%, and 74% had a coefﬁcient of variation #20%.
Statistical analysis. Baseline characteristics were summarized by insulin
resistance status. Metabolites with .20% missing or undetectable values were
excluded; 110 metabolites were analyzed. Metabolite levels were log trans-
formed due to right-skewed distribution, and paired Student t tests were
conducted to examine the differences between post- and pre-OGTT metabolite
levels. To account for multiple testing, a Bonferroni-corrected threshold, P ,
0.05/110 = 0.0005, was used to deﬁne a statistically signiﬁcant change in me-
tabolite levels with glucose challenge. Pearson correlation coefﬁcients were
calculated to identify groupings of metabolites.
Metabolites with a .1.2-fold change (based on the ratio of the log-transformed
metabolites) after OGTT were selected to test for differences between sub-
sets with and without insulin resistance. To minimize multiple hypothesis
testing, metabolites within the same grouping were only selected if there was
low-moderate correlation between metabolites (deﬁned as absolute r , 0.4).
Multivariable linear regression was used to test differences in OGTT me-
tabolite changes based on HOMA-IR and between groups with and without
insulin resistance; models were ﬁrst adjusted for age and sex and further
adjusted for BMI. Results were deemed signiﬁcant at a Bonferroni-corrected
threshold, P , 0.05/27 = 0.002. Least squares–adjusted mean differences
were graphed. To explore whether differences in metabolite excursion in
insulin-resistant individuals were potentially mediated by insulin effects, we
examined the relationship of insulin excursion during OGTT and the corre-
sponding metabolite excursion using multivariable linear regression.
In secondary analyses, metabolites with signiﬁcant changes during glucose
challenge were then included in a cluster-based analysis. The change in me-
tabolite with OGTT (D)w a sd e ﬁned as the log-post-OGTT metabolite level
minus the log-pre-OGTT metabolite level. The D in metabolite levels with
OGTT were rank normalized using the Bloomberg method, and correlated D
were classiﬁed into hierarchical groupings using cluster analysis (PROC
VARCLUS). Clusters were formed on the basis of principal components, using
eigenvalue thresholds of 1.
A cluster score was then calculated for each participant, based on the
average of the rank-normalized D for metabolites within each cluster. Multi-
variable regression models were used to examine the association of cluster
scores and glycemic traits, including insulin resistance, deﬁned as the upper
quartile of HOMA-IR in the nondiabetic participants of the Framingham Off-
spring cohort who attended exam 5; impaired glucose tolerance, deﬁned as
a 2-h post-OGTT glucose of 140–199 mg/dL; and impaired fasting glucose,
deﬁned as a fasting glucose 100–125 mg/dL. Models were ﬁrst adjusted for age
and sex and further adjusted for BMI. The study sampling scheme was
accounted for in PROC GLIMMIX. For clusters with signiﬁcant Bonferroni-
adjusted P values, the same regression models were performed on individual
metabolite D to examine the association of individual metabolites with each
glycemic trait.
All analyses were conducted using SAS 9.3 (Cary, NC), and PROC GLIMMIX
was used to account for the sampling scheme.
RESULTS
A total of 377 subjects (mean age 57 years, 42% women)
were included in this analysis. Due to the selection of
a sample with a high propensity for the development of
diabetes, half of the sample met the deﬁnition of insulin
resistance, with HOMA-IR in the top quartile of the full
nondiabetic FHS Offspring sample. Insulin-resistant indi-
viduals tended to have a higher prevalence of metabolic
syndrome or features of the metabolic syndrome (Table 1).
Insulin levels increased by 65 6 55 mIU/mL (P , 0.0001)
2 h after glucose challenge, and glucose levels increased
by 17 6 30 mg/dL (P , 0.0001) at 2 h post-OGTT in the
overall sample. Insulin and glucose excursion with OGTT
were positively correlated (r = 0.53, P , 0.0001). Partic-
ipants with insulin resistance had higher baseline insulin
levels, with higher insulin and glucose excursion after
OGTT, compared with those who were not insulin re-
sistant (insulin increased by 89 6 63 vs. 41 6 31 mIU/mL,
P , 0.0001; glucose increased by 24 6 29 vs. 10 6 29 mg/dL,
P , 0.0001).
Of the 110 metabolites that were detectable in at least
80% of the sample, 91 signiﬁcantly increased or decreased
in level after the glucose challenge (P # 0.0005 for all). The
majority of metabolites decreased in response to OGTT
(Table 2), whereas a few increased in response to glucose
challenge (Table 3). The largest relative decreases were
seen in b-hydroxybutyrate, which decreased by more than
fourfold after glucose challenge, and serotonin, which
decreased more than twofold. By contrast, the largest in-
crease was in hippurate (a known derivative of the pre-
servative benzoic acid found in glucola, the drink used
during OGTT) (12), which increased more than fourfold,
and phosphoglycerate, which increased by ;50%. Older
TABLE 1
Characteristics of sample by insulin resistance status
Insulin resistance
status
Total
(n = 377)
Normal
(n = 189)
Resistant
(n = 188)
Clinical characteristics
Age (years) 56.5 (8.8) 56.3 (8.8) 56.7 (8.8)
Women, % 42 44 40
BMI (kg/m
2) 30.2 (5.3) 28.4 (4.6) 32.0 (5.3)
Waist circumference (cm) 101 (13) 97 (12) 105 (12)
SBP (mmHg) 133 (18) 132 (19) 134 (17)
Antihypertensive
treatment, % 30 25 35
Current smoker, % 16 17 16
Metabolic syndrome, % 67 51 82
Laboratory characteristics
Fasting glucose (mg/dL) 105 (9) 103 (9) 106 (8)
2-h glucose (OGTT) (mg/dL) 122 (31) 113 (30) 131 (29)
Fasting insulin (mIU/mL) 12.8 (9.4) 6.4 (2.8) 19.2 (9.4)
HOMA-IR 3.3 (2.5) 1.6 (0.7) 5.0 (2.5)
Total cholesterol (mg/dL) 211 (36) 213 (39) 208 (33)
HDL cholesterol (mg/dL) 45 (13) 49 (14) 41 (11)
Triglycerides (mg/dL) 172 (105) 144 (86) 200 (114)
Data are presented as mean (SD) unless otherwise indicated.
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Metabolites that decreased after glucose challenge (paired Student t test, P , 0.0001 for all)
Metabolite Pathway group Mean change* SD Fold change
b-Hydroxybutyrate Ketone 21.51 0.72 4.51
Serotonin Tryptophan derivative 20.85 0.83 2.33
Hypoxanthine Purine 20.78 0.93 2.17
Xanthine Purine 20.52 0.57 1.68
Citrulline Urea cycle 20.50 0.15 1.65
Guanosine diphosphate Purine 20.49 0.72 1.63
Isoleucine Amino acid 20.47 0.14 1.60
Leucine Amino acid 20.45 0.15 1.57
Inosine Purine 20.40 0.49 1.49
Xanthurenate Amino acid metabolite 20.39 0.31 1.47
Propionate Organic acid 20.38 0.42 1.46
Guanosine monophosphate Purine 20.37 0.66 1.45
Methionine Amino acid 20.36 0.19 1.44
Gentisate Amino acid metabolite 20.34 0.47 1.41
Tyrosine Amino acid 20.34 0.14 1.41
Cholate Bile acid 20.33 0.82 1.40
Adenosine monophosphate Purine 20.33 0.76 1.39
Hydroxyproline Amino acid 20.31 0.15 1.37
Asparagine Amino acid 20.31 0.24 1.36
Adenosine diphosphate Purine 20.29 0.84 1.33
Salicylurate 20.28 0.46 1.33
Uridine diphosphate Pyrimidine 20.27 0.43 1.31
Niacinamide 20.27 0.40 1.31
Threonine Amino acid 20.27 0.11 1.31
Aspartate Amino acid 20.27 0.30 1.31
Phenylalanine Amino acid 20.26 0.14 1.30
Ornithine Urea cycle 20.25 0.25 1.29
Aminoadipate Amino acid metabolite 20.25 0.23 1.28
Serine Amino acid 20.24 0.17 1.27
Orotate Vitamin 20.24 0.28 1.27
Valine Amino acid 20.23 0.10 1.26
Uridine monophosphate Pyrimidine 20.23 0.46 1.25
Cystathionine Amino acid metabolite 20.22 0.32 1.25
Arginine Amino acid 20.22 0.35 1.24
Pyridoxate Vitamin 20.20 0.16 1.22
Deoxycholates Bile acid 20.19 0.41 1.21
Xanthosine 20.17 0.25 1.19
Lysine Amino acid 20.17 0.14 1.18
Histidine Amino acid 20.17 0.14 1.18
Tryptophan Amino acid 20.16 0.14 1.17
a-Hydroxybutyrate Organic acid 20.16 0.17 1.17
ADMA/SDMA 20.15 0.15 1.16
Ribose/ribulose phosphate Sugar 20.15 0.40 1.16
Thiamine 20.15 0.70 1.16
5-HIAA Tryptophan derivative 20.14 0.39 1.15
Glycine Amino acid 20.14 0.17 1.15
Glutamate Amino acid 20.14 0.21 1.15
NMMA 20.14 0.18 1.15
Proline Amino acid 20.14 0.09 1.15
Taurine 20.14 0.12 1.14
Hydroxyphenylacetate Amino acid metabolite 20.13 0.19 1.13
Indole propionate Amino acid metabolite 20.12 0.25 1.13
Oxalate Dicarboxylic acid 20.12 0.21 1.12
Fumarate/maleate TCA cycle 20.11 0.22 1.12
Flavin mononucleotide Vitamin 20.11 0.44 1.12
Aconitate TCA cycle 20.10 0.21 1.11
Glutamine Amino acid 20.10 0.26 1.10
Pantothenate Vitamin 20.09 0.15 1.10
Uridine Pyrimidine 20.09 0.16 1.10
Trimethylamine 20.09 0.24 1.09
Isocitrate TCA cycle 20.08 0.18 1.08
Methyladipate/pimelate Dicarboxylic acid 20.07 0.18 1.07
Glucuronate Sugar 20.07 0.23 1.07
Continued on next page
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fructose/lactose with OGTT (P = 0.0003). After adjustment
for age and baseline metabolite levels, women had greater
decreases in citrulline and xanthosine and greater increases
in bile acids, phosphoenolpyruvate, and glucose/fructose/
lactose with glucose challenge when compared with men
(P , 0.0005 for all) (Supplementary Table 1).
Correlated metabolites reﬂect biological pathways. In
analyses using a cluster-based approach, we found that
groupings of metabolites whose baseline concentrations
correlated, or whose responses to glucose challenge cor-
related, also reﬂected common underlying biological
groupings. For example, baseline amino acid concentrations,
as well as their responses to OGTT, were highly correlated
with each other (Supplementary Tables 2 and 3 and Fig. 1).
Insulin actions on known metabolic pathways. Changes
in metabolite levels in response to glucose challenge ap-
peared to be consistent across metabolic pathways (Fig. 2),
highlighting the multiple physiological actions of insulin.
Decreases in all amino acids and related metabolites pro-
vided evidence of decreased proteolysis. Similarly, a de-
crease in b-hydroxybutyrate and tricarboxylic acid (TCA)
cycle intermediates was consistent with inhibition of keto-
genesis and TCA cycle ﬂux. In contrast, products of gly-
colysis increased after glucose challenge. Our ﬁndings also
show a decrease in nitrogenous bases, including purines
and pyrimidines, in response to glucose challenge, consis-
tent with insulin-mediated stimulation of DNA and purine
biosynthesis across different tissues as seen in previous
experimental studies (13,14).
Insulin actions on novel biological pathways. We found
consistent changes in several biological pathways that
a r el e s se s t a b l i s h e di nr e l a t i o nt og l u c o s ea n di n s u l i n
metabolism (Fig. 3). Serotonin and its precursors/derivatives,
including 5-hydroxyindoleacetic acid (5-HIAA) and trypto-
phan, all decreased after glucose challenge. Metabolites of
the urea cycle, including citrulline, ornithine, and arginine,
all decreased. Nucleic acids and related metabolites de-
creased as well in response to OGTT. We also observed
decreases in a number of derivatives or cofactors related to
the B vitamins, a group of water-soluble vitamins essential
to cellular metabolism: niacinamide, the amide of nicotinic
acid (vitamin B3/niacin), is important in various oxidation-
reduction reactions; pyridoxate, an enzyme in the family of
TABLE 2
Continued
Metabolite Pathway group Mean change* SD Fold change
Alanine Amino acid 20.07 0.13 1.07
Sorbitol Sugar 20.07 0.19 1.07
Quinolinate Amino acid metabolite 20.07 0.16 1.07
Hydroxyglutarate Organic acid 20.06 0.25 1.07
Dimethylglycine Methyl 20.05 0.12 1.06
F1P/F6P/G1P/G6P Glycolysis 20.05 0.28 1.05
Adipate Dicarboxylic acid 20.05 0.23 1.05
Suberate Dicarboxylic acid 20.05 0.19 1.05
Sebacate Dicarboxylic acid 20.04 0.19 1.04
Urate Purine 20.03 0.10 1.03
ADMA, asymmetric dimethylarginine; F1P, fructose 1-phosphate; F6P, fructose 6-phosphate; G1P, glucose 1-phosphate; G6P, glucose 6-
phosphate; NMMA, N-monomethylarginine; SDMA, symmetric dimethylarginine. *Mean change represents log-post-OGTT value minus log-
pre-OGTT value.
TABLE 3
Metabolites that increased after glucose challenge (paired Student t test, P , 0.0001 for all)
Metabolite Group Mean change* SD Fold change
Hippurate Amino acid metabolite 1.53 0.80 4.63
Phosphoglycerate Glycolysis 0.39 0.61 1.48
Taurodeoxycholates Bile acid 0.34 0.86 1.41
Glycodeoxycholates Bile acid 0.30 0.82 1.35
a-Glycerophosphate Glycolysis 0.30 0.49 1.35
Taurocholate Bile acid 0.24 0.84 1.27
Glycocholate Bile acid 0.15 0.63 1.17
Glycerophosphocholine Methyl 0.14 0.38 1.16
Lactate Glycolysis 0.13 0.22 1.14
Phosphoenolpyruvic acid Glycolysis 0.10 0.33 1.11
Phosphocreatine 0.10 0.32 1.10
Glucose/fructose/lactose Sugar 0.06 0.24 1.06
Inositol Sugar 0.06 0.20 1.06
Creatine 0.05 0.14 1.05
Fructose/glucose/galactose Sugar 0.04 0.14 1.05
Carnitine 0.03 0.08 1.03
Choline Methyl 0.03 0.12 1.03
Betaine Methyl 0.03 0.08 1.03
*Mean change represents log-post-OGTT value minus log-pre-OGTT value.
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olism; thiamine (vitamin B1) is a coenzyme in glucose and
amino acid metabolism; ﬂavin mononucleotide is a de-
rivative of riboﬂavin (vitamin B2) and serves as a cofactor
for a various oxidoreductases; and pantothenate (vitamin
B5) is an essential cofactor for CoA synthesis and metabo-
lism of proteins, carbohydrates, and fats. Lastly, we observed
an increase in conjugated bile acids and a concomitant de-
crease in unconjugated bile acids in response to the glucose
challenge.
Effect of insulin resistance and other glycemic traits
on metabolite excursions. A total of 27 uncorrelated
(r , 0.4) metabolites had a .1.2-fold change after OGTT.
For ﬁve of these metabolites, the excursion after OGTT
was different in participants with normal insulin levels
compared with insulin-resistant individuals, including
b-hydroxybutyrate, isoleucine, lactate, orotate, and pyridoxate
(Table 4). The excursion of all metabolites except orotate
was blunted in insulin-resistant, compared with noninsulin-
resistant, individuals (Fig. 4). Of these metabolites, changes
in lactate, but not the other metabolites, were associated
with insulin excursion during OGTT in the overall sample
in exploratory analyses (P , 0.0001 after adjustment for
age, sex, and insulin resistance status) and remained as-
sociated after exclusion of insulin-resistant individuals
(P = 0.0005). When examined as a continuous variable, ad-
ditional suggestive differences were observed according to
HOMA-IR in taurodeoxycholates, niacinamide, and orni-
thine, with a blunted response in those with greater insulin
resistance (Supplementary Table 4).
In secondary analyses using a cluster-based approach,
changes in hydroxyphenylacitate and phosphoenolpyr-
uvate with OGTT had suggestive associations with fasting
glucose. Glucose/fructose/lactose, fructose/glucose/galactose,
FIG. 1. Heat map of correlated metabolite changes with glucose challenge.
J.E. HO AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 62, AUGUST 2013 2693and hippurate had signiﬁcant associations with 2-h post-OGTT
glucose, and b-hydroxybutyrate, tryptophan, a-hydroxybutyrate,
and ornithine had suggestive associations (Supplementary
Table 5).
DISCUSSION
Using a systematic approach, we have demonstrated per-
turbations in numerous metabolic and biological pathways
in response to a glucose challenge. Many pathways rep-
resent expected responses to the actions of insulin, in-
cluding alterations in glycolysis, lipolysis, ketogenesis, and
proteolysis. However, we also observed consistent effects
of glucose loading on a number of biological pathways that
have not previously been well described. Speciﬁcally, the
neurotransmitter serotonin (and related metabolites) was
suppressed more than twofold in response to glucose
challenge. In addition, we observed a consistent decrease
in the precursors or derivatives related to the B vitamins
after OGTT. Lastly, we identiﬁed differences in metabolite
responses between individuals with and without insulin
resistance, indicating that changes in metabolic phenotypes
may be unmasked by OGTT in the prediabetic state.
To our knowledge, ours is the largest study to date to
describe the physiological changes in metabolites after
OGTT. Several smaller studies have reported changes in
metabolites with glucose challenge in humans (8,15,16) and
animal models (17). Our group previously examined meta-
bolic proﬁling in response to glucose challenge in healthy
university students, with validation in a middle-aged subset
of 50 participants of the FHS (8). This study demonstrated
signiﬁcant changes in 18 metabolites, with some differences
in metabolite excursions related to baseline fasting insulin
levels. We now extend these ﬁndings to a far greater sample
size and demonstrate signiﬁcant changes in .90 metabo-
lites representing a number of distinct biological pathways
that are involved in the intrinsic biological response to a
glucose challenge.
There is a growing body of evidence demonstrating a
postprandial or postglucose increase in circulating conju-
gated bile acids (8,16). Glucose ingestion is known to
stimulate the release of cholecystokinin, signaling gallbladder
contraction and release of bile into the enterohepatic cir-
culation (18). Experimental evidence suggests that both
glucose and insulin rapidly induce cytochrome P-450 enzyme
cholesterol 7a-hydroxylase (CYP7A1) gene expression,
FIG. 2. Metabolite excursions after glucose challenge in metabolic pathways that reﬂect the effects of insulin. Notable perturbations include
decreased proteolysis (as evidenced by lower amino acids and amino acid metabolites), inhibition of ketogenesis (lower b-hydroxybutyrate),
suppression of the TCA cycle, and activation of glycolysis. % change = 100 3 (up-fold change – 1) or 100 3 (1 2 down-fold change).
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acid synthesis (19,20). Metabolic status also seems to
regulate expression of the farnesoid X receptor, a tran-
scription factor that controls bile acid synthesis (21), and
expansion of the bile acid pool in turn may be linked to
improved glucose homeostasis (22). We not only dem-
onstrate a robust increase in conjugated bile acids in re-
sponse to glucose challenge but also show a simultaneous
decrease in unconjugated bile acids, suggesting that con-
jugation, a process catalyzed by bile acid CoA:amino acid
N-acyltransferase (21), may be affected by postprandial in-
creases in glucose and/or insulin. Gut microbiota are
known to modify bile acids in a variety of different ways,
including deconjugation, dehydroxylation, oxydation, and
sulfation (23), and altered bile acid proﬁles have pre-
viously been linked to diabetes in a case-control study
(24). It is possible that alterations in gut microbial metab-
olism may have affected the bile acid proﬁle post–glucose
challenge.
One of the notable and unexpected ﬁndings of our study
was a consistent decrease in vitamins B1, B2, B3, B5, and
B6 after glucose challenge. The B vitamins are a group of
water-soluble vitamins essential to cellular metabolism.
Interestingly, this observation can be considered in the
context of a well-known clinical observation pertaining to
thiamine (B1), an essential cofactor for pyruvate de-
hydrogenase, an enzyme linking glycolysis and the citric
acid cycle, as well as a-ketoglutarate dehydrogenase, an
important enzyme in the citric acid cycle (25). Thiamine
deﬁciency is the cause of Wernicke’s encephalopathy, an
acute neurological disorder seen in the setting of chronic
excessive alcohol abuse. It has long been recognized that
symptoms of Wernicke’s encephalopathy can be precip-
itated rapidly after the institution of intravenous glucose
therapy in susceptible individuals (26). We now show that
a measurable decrease in thiamine occurs even in ostensi-
bly healthy individuals after glucose ingestion. The mecha-
nism for this decrease is unclear, although it may be that
increased glycolysis after glucose ingestion drives down
circulating plasma thiamine levels. Dynamic changes in the
other B vitamins after glucose challenge are of equal in-
terest, as many play essential roles in metabolic pathways
affected by insulin action, including amino acid metabo-
lism (B6), gluconeogenesis (B6), the TCA cycle (B5), and
various redox reactions (B2 and B3).
We observed a more than twofold decrease in serotonin
levels after glucose challenge, as well as a concomitant de-
crease in its precursor tryptophan and its main metabolite
FIG. 3. Metabolite excursions after glucose challenge in pathways that are not previously established in relation to glucose or insulin metabolism.
Notable perturbations include inhibition of the serotonin system, decrease in metabolites of the urea cycle, suppression of nucleic acids, decrease
in all vitamins of the B superfamily, increase in all conjugated bile acids, and decrease in deconjugated bile acids. % change = 100 3 (up-fold change
– 1) or 100 3 (1 2 down-fold change).
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portant role in energy and glucose homeostasis, an effect
that is mediated via central autonomic pathways in the
midbrain, as well as by peripheral release of serotonin
from gastrointestinal enterochromafﬁnc e l l s( 2 7 ) .I ne x p e r i -
mental studies, genetic deletion of the serotonin receptor
5-HT2c produced insulin resistance and type 2 diabetes
(28), and 5-HT2c agonists improved peripheral insulin ac-
tion (29). In turn, the effect of glucose load on circulating
serotonin levels has not been well described. A previous
study in 100 healthy individuals measured plasma neuro-
transmitters in response to OGTT and noted noradrenergic
over parasympathetic predominance at 2 h (30). Another
study showed postprandial increases in serotonin levels
after ingestion of a meal in healthy volunteers (31). These
results may contrast with our ﬁndings due to differences in
the ingested tryptophan content. Serotonin synthesis is
sensitive to the availability of tryptophan (32), and it may
be that decreases in serotonin follow decreased trypto-
phan concentrations in response to glucose challenge in
our study.
We observed ﬁve metabolites with differential changes in
response to glucose challenge in insulin-resistant individuals.
Interestingly, insulin resistance was associated with a blunted
excursion post-OGTT for b-hydroxybutyrate, isoleucine,
lactate, and pyridoxate. This conﬁrms that suppression of
ketogenesis (b-hydroxybutyrate), proteolysis (isoleucine),
and increased glycolysis (lactate) is likely mediated via in-
sulin actions, and that these effects are attenuated in the
insulin-resistant state. Furthermore, greater increases in in-
sulin during glucose challenge were associated with larger
increases in lactate in individuals with normal HOMA-IR.
Interestingly, there appear to be sex differences in cir-
culating fasting metabolite concentrations and their asso-
ciation with insulin action (33). We now show that there
are also sex differences in the dynamic response to glu-
cose challenge, emphasizing the potential role of hormonal
factors in the regulation of glucose homeostasis and di-
abetes pathogenesis (34).
It is thought that impaired fasting glucose predominantly
reﬂects a defect in early insulin secretion during OGTT and
hepatic insulin resistance, and impaired glucose tolerance
reﬂects both early and late defects in insulin secretion
during OGTT, and mostly insulin resistance at the level of
skeletal muscle (35). In exploratory analyses, we found a
blunted decrease in b-hydroxybutyrate, a-hydroxybutyrate,
tryptophan, and ornithine in individuals with higher 2-h
post-OGTT glucose, suggesting that suppression of keto-
genesis, proteolysis, and the urea cycle is blunted in these
individuals. This may possibly reﬂect a late-phase defect in
insulin secretion, although further studies are needed to
substantiate these ﬁndings.
Several limitations of the study deserve mention. Al-
though many metabolite changes were in concert with
known physiological actions of insulin, it is not possible in
our observational study to discern whether perturbations
could also have been due to effects of glucose excursion
during OGTT. Furthermore, enteric microbiota can inﬂuence
TABLE 4
Differences in metabolite changes following OGTT between insulin-resistant and non–insulin-resistant groups
Adjusted for age and sex Adjusted for age, sex, and BMI
Estimate* SE P value Estimate* SE P value
b-Hydroxybutyrate 0.280 0.072 ,0.001 0.258 0.077 0.001
Isoleucine 0.051 0.014 0.001 0.034 0.015 0.026
Lactate 20.064 0.022 0.005 20.040 0.024 0.094
Orotate 20.079 0.029 0.007 20.086 0.031 0.006
Pyridoxate 0.043 0.016 0.009 0.035 0.017 0.047
*Estimates represent the difference in metabolite excursions (log-post-OGTT value minus log-pre-OGTT value) after OGTT in insulin-resistant
vs. non–insulin-resistant individuals.
FIG. 4. Metabolite excursions after glucose challenge in participants
with and without insulin resistance. Analyses are adjusted for age, sex,
and BMI. Error bars represent 95% CIs. Changes for ketogenesis
(b-hydroxybutyrate), proteolysis (isoleucine), and glycolysis (lactate)
are all blunted in insulin-resistant individuals.
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changes seen with glucose challenge could in part be due to
effects on intestinal microbes, rather than pure insulin
effects. For example, plasma hippurate concentrations may
be elevated due to gut microbial metabolism of phenylala-
nine (37). It is possible that glucose ingestion stimulated
intestinal microbial metabolism, resulting in increased hip-
purate levels in our study, although other metabolites of
microbial metabolism (including propionate, dimethylgly-
cine, trimethylamine, and indoxylsulfate) (8) decreased
with glucose challenge. The effect of glucose challenge on
gut microbial contributions to changes in plasma metabo-
lites requires further study. Decreases in plasma metabo-
lites could be in part related to a dilutional effect with the
volume ingested during glucose challenge. However, in a
previous study that diluted the 75-g OGTT by up to three-
fold, most differences in measured glucose were observed
early in the test, with no difference in 2-h values, indicating
that this effect may be minimal in our study, which only
measured metabolites at the 2-h time point (38). Further-
more, the varying directionality and broad range in change
among different analytes would argue against a simple
dilutional effect. We used a targeted approach with a com-
bination of LC and tandem MS to identify metabolites. Al-
though this system is less biased than other techniques, such
as nuclear magnetic resonance spectroscopy, it allowed for
highly speciﬁc identiﬁcation of metabolites. We were not
able to provide absolute concentrations for all metabolites,
and studies of absolute quantitation of metabolites remain
important areas of future investigation. Lastly, the FHS is a
predominantly Caucasian middle-aged cohort, and the
sample in this study included individuals with a high pro-
pensity for the development of diabetes, with a large pro-
portion meeting the criteria for insulin resistance; therefore,
our ﬁndings may not be generalizable to other populations.
In summary, we found changes in distinct metabolic and
biological pathways in response to glucose challenge. Al-
though alterations in glycolysis, lipolysis, ketogenesis, and
proteolysis are known effects of insulin action, we also
found consistent changes in the serotonergic system and
multiple members of the B vitamins after glucose chal-
lenge. These ﬁndings may further elucidate the metabolic
pathways regulating glucose homeostasis. We also identi-
ﬁed differences in metabolite responses between individ-
uals with normal insulin and insulin resistance, indicating
that changes in metabolic phenotypes associated with the
prediabetic state may be unmasked by OGTT. Further
studies investigating the distinct biological pathways
identiﬁed in our study may lead to a better understanding
of the adaptive versus maladaptive processes involved in
glucose and insulin metabolism.
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